These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 21068703)

  • 41. The effects of botulinum toxin on ocular tissue.
    Smith H
    Nurs Times; 1995 Jan 25-31; 91(4):41-3. PubMed ID: 7862573
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia.
    Han Y; Stevens AL; Dashtipour K; Hauser RA; Mari Z
    J Neurol; 2016 Apr; 263(4):772-80. PubMed ID: 26914922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Contributions and limitations for botulinum toxin injections for extrapyramidal diseases].
    Hinault P
    Rev Neurol (Paris); 2000 Dec; 156(12):1171-7. PubMed ID: 11139738
    [No Abstract]   [Full Text] [Related]  

  • 44. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG; Tyrrell EG; Grosset KA
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical symptoms, diagnosis and treatment of focal dystonias].
    Klivényi P; Vécsei L
    Orv Hetil; 2001 Oct; 142(42):2293-7. PubMed ID: 11760645
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Craniocervical dystonia: clinical and pathophysiological features.
    Colosimo C; Suppa A; Fabbrini G; Bologna M; Berardelli A
    Eur J Neurol; 2010 Jul; 17 Suppl 1():15-21. PubMed ID: 20590803
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A.
    Wohlfarth K; Kampe K; Bigalke H
    Mov Disord; 2004 Mar; 19 Suppl 8():S65-7. PubMed ID: 15027057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patient Characteristics and Real-World Use of Botulinum Toxins for the Treatment of Cervical Dystonia, Blepharospasm, and Hemifacial Spasm.
    Hast MA; Kong AM; Desai S; Back S; Syed S; Holmes J
    Toxins (Basel); 2024 Aug; 16(8):. PubMed ID: 39195772
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reply: Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial.
    Mueller J
    Mov Disord; 2009 May; 24(7):1098-9; author reply 1100. PubMed ID: 18942082
    [No Abstract]   [Full Text] [Related]  

  • 51. Cervical radiculopathy following botulinum toxin therapy for cervical dystonia.
    Defazio G; Lepore V; Melpignano C; Lamberti P; Livrea P; Ferrari E
    Funct Neurol; 1993; 8(3):193-6. PubMed ID: 8406138
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Blepharospasm: treatment with botulinum toxin].
    Barbosa ER; Silva HC; Haddad MS; Bittar MS
    Rev Hosp Clin Fac Med Sao Paulo; 1996; 51(6):220-3. PubMed ID: 9239894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Self-reported benefit and weakness after botulinum toxin in dystonia.
    Kassavetis P; Lungu C; Ehrlich D; Alter K; Karp BI
    Parkinsonism Relat Disord; 2020 Nov; 80():10-11. PubMed ID: 32927341
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical Dystonia.
    Tilden D; Guarnieri C
    Value Health; 2016; 19(2):145-52. PubMed ID: 27021747
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Botulinum toxin treatment of blepharospasm.
    Elston JS
    Adv Neurol; 1988; 50():579-81. PubMed ID: 3400511
    [No Abstract]   [Full Text] [Related]  

  • 57. [Mechanism of action, clinical indication and results of treatment of botulinum toxin].
    Lagueny A; Burbaud P
    Neurophysiol Clin; 1996; 26(4):216-26. PubMed ID: 8975111
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Botulinum toxin in movement disorders.
    Papapetropoulos S; Singer C
    Semin Neurol; 2007 Apr; 27(2):183-94. PubMed ID: 17390263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Botulinum toxin and dystonias.
    Drug Ther Bull; 1991 Dec; 29(26):102-3. PubMed ID: 1790760
    [No Abstract]   [Full Text] [Related]  

  • 60. Treatment of cervical dystonia with botulinum toxin.
    Jankovic J
    Mov Disord; 2004 Mar; 19 Suppl 8():S109-15. PubMed ID: 15027062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.